These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Phenotypic spectrum of Charcot-Marie-Tooth disease due to LITAF/SIMPLE mutations: a study of 18 patients. Guimarães-Costa R; Iancu Ferfoglia R; Leonard-Louis S; Ziegler F; Magy L; Fournier E; Dubourg O; Bouche P; Maisonobe T; Lacour A; Moerman A; Latour P; Stojkovic T Eur J Neurol; 2017 Mar; 24(3):530-538. PubMed ID: 28211240 [TBL] [Abstract][Full Text] [Related]
32. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L; Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074 [TBL] [Abstract][Full Text] [Related]
33. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Sereda MW; Meyer zu Hörste G; Suter U; Uzma N; Nave KA Nat Med; 2003 Dec; 9(12):1533-7. PubMed ID: 14608378 [TBL] [Abstract][Full Text] [Related]
34. CAL02, a novel antitoxin liposomal agent, in severe pneumococcal pneumonia: a first-in-human, double-blind, placebo-controlled, randomised trial. Laterre PF; Colin G; Dequin PF; Dugernier T; Boulain T; Azeredo da Silveira S; Lajaunias F; Perez A; François B Lancet Infect Dis; 2019 Jun; 19(6):620-630. PubMed ID: 31056427 [TBL] [Abstract][Full Text] [Related]
35. Motor performance deterioration accelerates after 50 years of age in Charcot-Marie-Tooth type 1A patients. Tozza S; Bruzzese D; Pisciotta C; Iodice R; Esposito M; Dubbioso R; Ruggiero L; Topa A; Spina E; Santoro L; Manganelli F Eur J Neurol; 2018 Feb; 25(2):301-306. PubMed ID: 29053907 [TBL] [Abstract][Full Text] [Related]